Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.9600 (3.23%) ($8.4000 - $9.1000) on Fri. Sep. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.69% (three month average) | RSI | 71 | Latest Price | $8.9600(3.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.9% a day on average for past five trading days. | Weekly Trend | HTBX advances 7.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) XBI(34%) ARKK(32%) ACES(30%) BLOK(30%) | Factors Impacting HTBX price | HTBX will decline at least -5.845% in a week (0% probabilities). VXX(-19%) VIXM(-17%) UUP(-14%) IGOV(-4%) XLU(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -5.845% (StdDev 11.69%) | Hourly BBV | 0.1 () | Intraday Trend | 5.8% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $9.21(-2.71%) | 10 Day Moving Average | $9.11(-1.65%) | 20 Day Moving Average | $8.69(3.11%) | To recent high | -64.6% | To recent low | 66.2% | Market Cap | $986m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |